DC-CIK as a widely applicable cancer immunotherapy.

Journal Article (Journal Article;Review)

Introduction: Immunotherapy is now a standard treatment for many malignancies. Although immune checkpoint inhibition has demonstrated substantial efficacy by enhancing T cell activation and function in the tumor microenvironment, adoptive transfer of T and NK cell products promises to provide activated cells capable of immediate and direct tumor destruction. A widely applicable, non-MHC dependent, cellular therapy, consisting of in vitro generated dendritic cells (DC) combined with cytokine-induced killer cells (CIK), is highly efficient to produce from individual patients and has demonstrated safety and efficacy alone or with chemotherapy.Areas covered: We summarize the clinical data from studies of DC-CIK and discuss future research directions.Expert opinion: Patients with a wide variety of tumor types who have received DC-CIK therapy may experience clinical responses. This versatile therapy synergizes with other anti-cancer therapies including chemotherapy and immunotherapy.

Full Text

Duke Authors

Cited Authors

  • Wang, S; Wang, X; Zhou, X; Lyerly, HK; Morse, MA; Ren, J

Published Date

  • June 2020

Published In

Volume / Issue

  • 20 / 6

Start / End Page

  • 601 - 607

PubMed ID

  • 32033522

Pubmed Central ID

  • 32033522

Electronic International Standard Serial Number (EISSN)

  • 1744-7682

Digital Object Identifier (DOI)

  • 10.1080/14712598.2020.1728250


  • eng

Conference Location

  • England